Jefferies Financial Group Inc. Invests $988,000 in Solventum Corporation $SOLV

Jefferies Financial Group Inc. purchased a new position in shares of Solventum Corporation (NYSE:SOLV) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 12,474 shares of the company’s stock, valued at approximately $988,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hilltop National Bank raised its holdings in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in Solventum in the 3rd quarter valued at about $25,000. JNBA Financial Advisors raised its holdings in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in Solventum in the 2nd quarter valued at about $28,000. Finally, City State Bank raised its holdings in Solventum by 166.7% in the 4th quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after buying an additional 240 shares during the period.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. The trade was a 41.39% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.24% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SOLV. KeyCorp boosted their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Rothschild & Co Redburn began coverage on shares of Solventum in a report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective on the stock. BTIG Research restated a “buy” rating and issued a $89.00 price objective on shares of Solventum in a report on Wednesday, May 6th. UBS Group lowered shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Thursday, May 14th. Finally, Piper Sandler dropped their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Eight analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $84.25.

Solventum Stock Performance

NYSE SOLV opened at $75.98 on Friday. The company has a market cap of $13.16 billion, a P/E ratio of 9.31, a P/E/G ratio of 1.17 and a beta of 0.59. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The stock has a 50-day moving average of $69.41 and a two-hundred day moving average of $75.04. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20.

Solventum (NYSE:SOLV) last released its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.